SRA International, Inc. to Acquire Constella Group, LLC
FAIRFAX, VA, June 20, 2007-SRA International, Inc. (NYSE: SRX), a leading provider of technology and strategic consulting services and solutions to federal government organizations, today announced the signing of a definitive agreement to acquire Constella Group, LLC, a privately-held provider of global health consulting services.
Headquartered in Durham, NC, Constella employs more than 1500 professionals organized by three interrelated service offerings: domestic health sciences, international health development, and global drug development. The domestic health sciences business provides research, technology, communications, and strategy support to U.S. government agencies charged with protecting and advancing the health of their constituents. Constella’s international health development business helps emerging nations across the world create and implement health policy, primarily through contracts with the governments of the U.S. and the United Kingdom. The global drug development business provides blue-chip pharmaceutical, biotechnology, and medical device firms with the strategic insight and services needed to take a drug, biologic or device through the development process from concept to market. The company’s combination of capabilities, domain expertise, and geographic reach enable it to offer differentiated solutions to address the world’s most complex health issues. Constella acquired two companies during calendar year 2006. Excluding pre-acquisition revenue for those two companies, Constella revenue for calendar year 2006 was approximately $169 million.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.